Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham.
Department of Pathology, Children's of Alabama, Birmingham, AL.
J Pediatr Hematol Oncol. 2020 Nov;42(8):e795-e797. doi: 10.1097/MPH.0000000000001474.
Langerhans cell histiocytosis (LCH) often has a recurrent and refractory course despite multiagent treatment modalities. Common relapse treatments include intense or prolonged cytotoxic chemotherapy regimens. There are a few prior reports that the nonsteroidal anti-inflammatory drug indomethacin demonstrated activity against bone LCH. Here we report indomethacin as a successful treatment for a case of chronic skin LCH that failed multiple prior chemotherapy regimens. This experience supports the need for trials to investigate indomethacin as a treatment for LCH both in the relapsed or refractory setting as well as potential combination or maintenance therapy in newly diagnosed patients.
朗格汉斯细胞组织细胞增生症 (LCH) 尽管采用了多种治疗方法，但常常具有复发性和难治性。常见的复发治疗包括强化或延长细胞毒性化疗方案。有少数先前的报告表明，非甾体类抗炎药吲哚美辛对骨 LCH 具有活性。在这里，我们报告吲哚美辛成功治疗了一例慢性皮肤 LCH 病例，该病例先前多次化疗方案均失败。这一经验支持有必要进行试验，以研究吲哚美辛作为 LCH 的治疗方法，无论是在复发或难治性情况下，还是作为新诊断患者的潜在联合或维持治疗。
